BNP PARIBAS SA reduces its holding of JUNSHI BIO (01877) by 1,192,600 shares at a price of HK$26.18 per share.
On April 9, BNP PARIBAS SA reduced its holdings in China Resources Pharmaceutical Group Limited (01877) by 1.1926 million shares, with a price of 26.18 Hong Kong dollars per share, for a total amount of approximately 312.23 million Hong Kong dollars.
According to the latest data from the Hong Kong Stock Exchange, on April 9th, BNP PARIBAS SA reduced its holding of JUNSHI BIO (01877) by 1.1926 million shares, at a price of 26.18 Hong Kong dollars per share, with a total amount of approximately 31.223 million Hong Kong dollars. After the reduction, the latest number of shares held is 27.9848 million, with the latest shareholding ratio of 10.75%.
Related Articles
US Stock Market Move | Wells Fargo & Company (WFC.US) fell over 6% as Q1 net interest income was below expectations.
SAINT BELLA GP(02508): The trustee purchased a total of 247,000 shares according to the stock reward plan.
HOMELAND ITL (03798) spent 269,800 Hong Kong dollars to repurchase 200,000 shares on April 14.
US Stock Market Move | Wells Fargo & Company (WFC.US) fell over 6% as Q1 net interest income was below expectations.
SAINT BELLA GP(02508): The trustee purchased a total of 247,000 shares according to the stock reward plan.
HOMELAND ITL (03798) spent 269,800 Hong Kong dollars to repurchase 200,000 shares on April 14.
RECOMMEND
CICC: Why Have Earnings Trajectories Diverged Across US, A‑Share, And Hong Kong Markets?
14/04/2026
HKEX Introduces Two Cross‑Market Hard Technology Indices; Five Mainland Fund Subsidiaries In Hong Kong Receive First ETF Authorizations
14/04/2026
Consecutive Success As Rocket Achieves “One Rocket, Eight Satellites,” China’s Commercial Spaceflight Enters The Dedicated‑Ride Era
14/04/2026
